SiBone (SIBN) Competitors $15.68 -0.64 (-3.92%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$15.70 +0.02 (+0.13%) As of 08/8/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SIBN vs. PRCT, WRBY, LIVN, EYE, LMAT, CNMD, LQDA, ENOV, AORT, and CDREShould you be buying SiBone stock or one of its competitors? The main competitors of SiBone include PROCEPT BioRobotics (PRCT), Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), LeMaitre Vascular (LMAT), CONMED (CNMD), Liquidia Technologies (LQDA), Enovis (ENOV), Artivion (AORT), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. SiBone vs. Its Competitors PROCEPT BioRobotics Warby Parker LivaNova National Vision LeMaitre Vascular CONMED Liquidia Technologies Enovis Artivion Cadre SiBone (NASDAQ:SIBN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in SIBN or PRCT? 98.1% of SiBone shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media refer more to SIBN or PRCT? In the previous week, PROCEPT BioRobotics had 6 more articles in the media than SiBone. MarketBeat recorded 23 mentions for PROCEPT BioRobotics and 17 mentions for SiBone. SiBone's average media sentiment score of 0.51 beat PROCEPT BioRobotics' score of 0.33 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive PROCEPT BioRobotics 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, SIBN or PRCT? SiBone has higher earnings, but lower revenue than PROCEPT BioRobotics. SiBone is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSiBone$167.18M4.05-$30.91M-$0.56-28.00PROCEPT BioRobotics$224.50M9.52-$91.41M-$1.55-24.78 Which has more volatility & risk, SIBN or PRCT? SiBone has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Do analysts rate SIBN or PRCT? SiBone presently has a consensus target price of $23.67, indicating a potential upside of 50.94%. PROCEPT BioRobotics has a consensus target price of $74.88, indicating a potential upside of 94.94%. Given PROCEPT BioRobotics' higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than SiBone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SiBone 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00PROCEPT BioRobotics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is SIBN or PRCT more profitable? SiBone has a net margin of -12.83% compared to PROCEPT BioRobotics' net margin of -30.60%. SiBone's return on equity of -14.20% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets SiBone-12.83% -14.20% -10.38% PROCEPT BioRobotics -30.60%-23.73%-17.34% SummarySiBone and PROCEPT BioRobotics tied by winning 8 of the 16 factors compared between the two stocks. Get SiBone News Delivered to You Automatically Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SIBN vs. The Competition Export to ExcelMetricSiBoneMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$676.44M$6.78B$5.48B$9.71BDividend YieldN/A1.33%4.59%4.12%P/E Ratio-28.0024.5230.1124.70Price / Sales4.0559.30454.41110.27Price / CashN/A21.3524.8428.01Price / Book3.944.728.515.76Net Income-$30.91M$178.18M$3.27B$267.05M7 Day Performance-12.40%-1.33%4.59%3.13%1 Month Performance-8.84%-2.89%0.89%1.27%1 Year Performance12.16%5.71%36.22%22.83% SiBone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIBNSiBone4.05 of 5 stars$15.68-3.9%$23.67+50.9%+12.2%$676.44M$167.18M-28.00350Earnings ReportAnalyst DowngradeAnalyst RevisionPRCTPROCEPT BioRobotics3.4214 of 5 stars$49.60-0.7%$84.13+69.6%-37.2%$2.76B$249.12M-29.18430Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionWRBYWarby Parker1.9905 of 5 stars$24.47+3.7%$23.13-5.5%+77.6%$2.47B$771.32M-203.883,780Trending NewsAnalyst ForecastLIVNLivaNova2.1974 of 5 stars$42.76+4.0%$59.29+38.6%+11.1%$2.24B$1.25B-10.452,900Trending NewsEarnings ReportAnalyst UpgradeEYENational Vision2.9976 of 5 stars$25.07+3.6%$24.18-3.5%+120.2%$1.91B$1.82B-75.9713,411Trending NewsEarnings ReportAnalyst UpgradeLMATLeMaitre Vascular2.3592 of 5 stars$84.36+4.1%$97.83+16.0%+10.2%$1.83B$219.86M42.61490Trending NewsEarnings ReportInsider TradeAnalyst RevisionCNMDCONMED3.9817 of 5 stars$53.46+2.2%$59.80+11.9%-18.4%$1.62B$1.31B15.153,900Dividend AnnouncementLQDALiquidia Technologies3.68 of 5 stars$19.48+10.2%$26.89+38.0%+75.5%$1.51B$14M-12.3350Upcoming EarningsENOVEnovis3.8103 of 5 stars$26.61+3.4%$55.60+109.0%-34.4%$1.47B$2.11B-1.917,367Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionAORTArtivion2.3021 of 5 stars$32.06+3.7%$32.40+1.1%+64.5%$1.32B$388.54M-64.121,600Trending NewsEarnings ReportAnalyst ForecastGap UpCDRECadre2.762 of 5 stars$33.09+2.3%$37.50+13.3%-9.8%$1.31B$567.56M34.832,284Trending NewsEarnings ReportAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies PROCEPT BioRobotics Competitors Warby Parker Competitors LivaNova Competitors National Vision Competitors LeMaitre Vascular Competitors CONMED Competitors Liquidia Technologies Competitors Enovis Competitors Artivion Competitors Cadre Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SIBN) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SiBone Please log in to your account or sign up in order to add this asset to your watchlist. Share SiBone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale